Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD).
For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).
Expanded access, also called “compassionate use,” may be an option for individuals who do not qualify for enrollment in ongoing clinical trials to gain early access to investigational new drugs that are not yet approved by the US Food and Drug Administration (FDA) and for which evidence of safety and efficacy has not been confirmed. Individuals with serious or life-threatening conditions for which no other therapeutic options are available may be eligible for treatment through an expanded access program.
Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through developing potential medical counter-measures. Our lead product candidate, Tonmya®, or TNX-102 SL (cyclobenzaprine hydrochloride sublingual tablets), is in Phase 3 development as a bedtime treatment for posttraumatic stress disorder (PTSD). PTSD is a serious condition characterized by chronic disability and overall high utilization of healthcare services, carrying significant social and economic costs as well as a heavy burden of human suffering in patients and their families.
At Tonix, we conduct randomized, controlled trials (RCTs) to study the safety and efficacy of our investigational new drugs. The safety and efficacy results from RCTs form the basis for regulatory authorities’ decisions on whether or not to approve new treatments. If approved, these treatments become widely available to the public and further empower physicians in treating their patients. We encourage patients to participate in clinical trials, both to help others with the same ailment and to contribute to greater scientific understanding of their disease and of the drugs being investigated as possible therapeutic alternatives.
We are currently recruiting PTSD patients for a Phase 3 trial, the RECOVERY study, in the United States. For further information on the RECOVERY study, visit:
Tonix does not currently offer investigational new drug TNX-102 SL for expanded access use. If you are suffering from military-related PTSD and are not eligible for our clinical trial, you can talk with your doctor about other available treatments, including FDA-approved medications for PTSD. You can also visit www.clinicaltrials.gov to find other PTSD clinical trials and see whether you are eligible to enroll in any of those trials.
The FDA has designated Tonmya®/TNX-102 SL a Breakthrough Therapy for the treatment of PTSD. Our expert development team is fully committed to bringing this innovative treatment to market as quickly as possible.
Our expanded access policy will be continuously reassessed, and any updates will be provided on our website. For further information, you can contact us at: firstname.lastname@example.org. We will respond to any questions you may have within one week.
Thank you for your interest in Tonix Pharmaceuticals and in our investigational new drug, Tonmya®/TNX-102 SL.